Complex Association between Alanine Aminotransferase Activity and Mortality in General Population: A Systematic Review and Meta-Analysis of Prospective Studies

Zhengtao Liu1,2*, Huaijun Ning3#, Shuping Que3,4, Linlin Wang4, Xue Qin5, Tao Peng1,6*

1 Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China, 2 National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Medical University, Nanning, China, 3 Department of Pediatrics, Women and children’s hospital of Guangxi, Nanning, China, 4 Department of Pediatrics, First Affiliated Hospital of Guangxi Medical University, Nanning, China, 5 Clinical Laboratory Center, First Affiliated Hospital of Guangxi Medical University, Nanning, China, 6 Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Guangxi Medical University, Nanning, China

Abstract

Objective: Controversy exists in using alanine aminotransferase (ALT) activity for predicting long-term survival. Therefore, this research study investigated the association between ALT activity and mortality through a systematic review and meta-analysis of previous prospective studies.

Methods: Electronic literature databases, including PubMed, Embase, and the Institute for Scientific Information (ISI), were searched for relevant prospective observational studies (published before Dec 30, 2013) on the association between baseline ALT activity and ensuing all-cause/disease-specific mortality. Information on nationality, sample size, participant characteristics, follow-up duration, comparison, outcome assessment, hazard ratios (HRs) and adjusted covariates was extracted. Pooled HRs and corresponding 95% confidence intervals (CIs) were separately calculated for categorical risk estimates (highest vs. lowest ALT categories) and continuous risk estimates (per 5 U/l of ALT increment) in subgroups separated by age (<70/≥70 years).

Results: A total of twelve prospective cohort studies, totaling 206,678 participants and 16,249 deaths, were identified and analyzed. In the younger age group, the pooled HR for mortality related to liver-disease was about 1.24 (95% CI: 1.23–1.25) per 5 U/l of ALT increment. The dose-response HRs of all-cause mortality, cardiovascular (CV) disease-related mortality, and cancer-related mortality were 0.91 (0.88–0.94), 0.91 (0.85–0.96), 0.92 (0.86–0.98) respectively per 5 U/l of ALT elevation, with insignificant heterogeneity in the older population. There was an approximate decrease of 4% observed on HRs of all-cause, CV-related, and cancer-related mortality followed with one year’s increment through meta-regression (all P<0.05).

Conclusions: The ALT-mortality association was inconsistent and seems particularly susceptible to age after synthesizing the previous prospective studies. In terms of the age, ALT activity was more valuable in predicting mortality in the older population; extremely low ALT levels indicated a higher all-cause, CV-related, and cancer-related mortality. ALT activity may therefore be a useful biomarker when predicting the long-term survival of elderly patients.

Introduction

Measurements of serum alanine aminotransferase (ALT) activity is an available and low-cost biochemical assay in annual health check-ups. Serum ALT activity is not only a biomarker for monitoring liver damage, but is also a predictor for evaluating overall health [1,2]. In previous epidemiological prospective cohort surveys [3–5], elevated ALT activity was associated with all-cause/cause specific (including cardiovascular (CV) disease, cancer, and liver disease) mortality in long-term follow-up duration. The elevated ALT activity was potentially indicative of unrecognized liver disease that especially caused deaths in populations with a high prevalence of viral hepatitis [3]. On the other hand, elevated ALT activity was a potential predictor of CV disease that might add to a risk of death through the metabolic...
syndrome (MetS) [6,7]. However, these associations have been inconsistent and controversial as some prospective studies have failed to observe a significant association between ALT activity and mortality [8–14].

Recently, lower ALT activity was linked to decreased long-term survival in older population [13,15,17–19]. The clinical significance of extra low ALT activity as a reliable biomarker for predicting increased mortality, especially in aging population (mean age >70 years) [13,15–18], has caused worldwide concern. The possible interpretation is that the lower ALT activity indicates aging and frailty [19–22] in overall health, decreased size and reduced blood flow of the liver [23,24], which might increase susceptibility to a number of diseases.

The association between ALT activity and mortality is complex, inconsistent and controversial. One study that examined prior prospective studies indicated that increased age and ensuing frailty might be a possible confounder in the ALT-mortality association [25]. Age may play a crucial role in mediating the ALT-mortality association [26]; however, the pooled risks of mortality caused by ALT variation and the exact effects of age on this association have never been assessed. Therefore, a systematic review and meta-analysis of previous prospective cohort studies classified by mean age (<70/≥70 years) was performed to evaluate the pooled effect of ALT activity on the risk of all-cause/case-specific mortality. In addition, the exact effect of age on this association was quantified through meta-regression. Furthermore, subgroup and sensitivity analysis was conducted to search for other potential confounders that might cause heterogeneity in synthetic analysis. To the best of our knowledge, this is the first systematic review and meta-analysis to evaluate the association between ALT activity and all-cause/disease-specific mortality.

Materials and Methods

PRISMA and flow diagram

The meta-analysis was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [27]. The supporting PRISMA checklist and flow diagram for this meta-analysis is available as supporting information; see Checklist S1 and Flow Diagram S1, respectively.

Search strategy and study selection

An extensive relevant literature search was conducted in PubMed, Embase and the Institute for Scientific Information (ISI) database, without language restrictions, through help from a qualified librarian (last updated at Dec 30th, 2013). The search was restricted to studies conducted in human subjects. Medical subject headings “alanine aminotransferase”, “transaminase”, “liver enzyme”, “ALT”, and “mortality” were used for searching the relevant literatures. The following search terms were used in PubMed: (alanine aminotransferase [All Fields] OR alanine aminotransferase [MeSH] OR transaminase [MESH] OR transaminase [All Fields] AND mortality [MeSH]). Similar search terms were applied to Embase and ISI (see Table S1). In addition, a manual search of citations from relevant original studies and review articles was performed. The reporting of this systematic review and meta-analysis were performed in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [28].

Only reports fulfilling the following inclusion criteria were included in the systematic review and meta-analysis: 1) prospective cohort studies published with original data, 2) ALT levels and mean age range of study participants at baseline were reported, and all-cause (essential) and/or cause-specific (including CV, cancer, and liver disease; dispensable) related mortality was an end point associated with ALT activity, 3) the hazard ratio (HR) or relative risk (RR) of mortality in the population with the lowest ALT category was treated as reference data, 4) studies that contained the minimum information necessary to estimate the continuous or dichotomous HR or RR of all-cause/case-specific mortality caused by ALT elevation compared in the same population were provided or obtained by calculation. If data were duplicated in more than one study, the most recent study was included in the analysis. Literature reviews, retrospective cohort studies, twins studies, case-control studies, case-cohort studies, and animal studies were excluded.

Quality assessment

The quality of each study was independently assessed through two authors using the Newcastle-Ottawa Scale (NOS) [29]. The NOS consists of three parameters of quality: selection, comparability, and outcome for cohort studies (Table S2). The NOS assigned a maximum of four stars for selection, two stars for comparability, and three stars for outcome. Therefore, nine stars reflected the highest quality. Studies with more than six stars were considered high quality. When discrepancies occurred, a joint reevaluation of the original article was performed with a third author.

Outcome measures and data extraction

Mortality outcomes consisted of all-cause mortality and the following cause-specific mortality were based on death certificates with underlying cause of death coded according to the International Classification of Diseases, Ninth Revision (ICD-9) [30]: CV mortality included the following subgroups according to ICD-9: coronary heart disease (ICD-9 410 to 414), congestive heart failure (ICD-9 428, 429), other cardiovascular disease (ICD-9 401 to 405, 440 to 443), stroke (ICD-9 430 to 438), cancer mortality (ICD-9 140–239), and liver disease mortality (ICD-9 70.2–70.9, 275.0–275.1, and 570–573).

Two authors independently extracted information using a standardized reporting form with predefined criteria specifically for this review. Study characteristics recorded were extracted as follows: first author, publication year, country of origin, study characteristics (numbers of participants and cases, definition of normal ALT value and percentage of participants in normal range, gender category, mean age range of populations, measures of outcome, follow-up durations, comparison style, adjusted HR or RR of mortality estimated from multivariable analysis according to the comparison style referred before and adjusted covariates in detail). When effects estimated in the same population were reported in different follow-up durations, only data with the longest follow-up time were included.

Statistical analysis

HR was selected as the effect to assess the association between ALT and all-cause/disease-specific mortality. RR was treated as HR. Data analyses used the most multivariate-adjusted HR and 95% CI. If the publications reported separate HR for gender or age, the pooled HRs were separately pooled as independent data points in subsequent meta-analysis. Otherwise, the separate HRs were combined.

To distinguish the clinical significance of ALT activity in different age groups, all of the enrolled studies were divided into two separate groups by mean age (<70/≥70 years). The pooled HRs were calculated with the use of STATA METAN [31]. The separate HRs reported in subgroups categorized by body mass index (BMI) were reevaluated by combining the enrolled number
and the death case under a different ALT level range with the use of STATA METAN [31]. Second, the combined HRs of all-cause, CV disease-related, cancer-related, and liver disease-related mortality were calculated between higher and lower ALT levels using the most fully adjusted covariates estimated in the younger and older population separately. Third, the dose-response HR of all-cause, CV disease-related, cancer-related, and liver disease-related mortality with 5 U/l of ALT increment in the two separate groups was calculated according to reported data (categories of ALT levels on median dose, number of cases and participants, and effect estimates with corresponding standard errors were required) using a method previously proposed [32,33]. Median or mean values in each group were presented according to categories of ALT activity. When this information was not reported, the midpoint of the upper and lower boundaries (as the approximate medians) was assigned. When the highest category was open-ended, the lower end value of the category multiplied by 1.2 was assigned [33]. Pooled HRs of disease-specific deaths caused by 5 U/l of ALT increment were then estimated to further analyze the association between ALT activity and disease-specific mortality.

To explore the influence of age on the association between ALT levels and all-cause/disease-specific mortality, meta-regression analyses were performed with the METAREG command [34]. The robustness of findings with respect to different assumptions was estimated by conducting a sensitivity analysis with METAINF command to search for outliers that might be the main origin of the heterogeneity in the overall analysis. Outliers identified were omitted and the impact was re-evaluated in the residual studies.

Furthermore, subgroup analysis was performed on enrolled studies divided by gender, ethnicity, follow-up duration, sample size, comparisons, observational indicator, previous use of statin medication, whether mainly (>95%) in the self-defined normal range of ALT levels, whether adjusted for alcohol intake, and MetS components (four or more MetS components adjusted according to the NCEP-ATP-III criteria [35]) as covariates in younger and older subgroups (classified by mean age ≤70 years/≥70 years, respectively). All the subgroup analysis aimed to explore the sources of potential variability in examining the association between ALT level and all-cause/disease-specific mortality.

The heterogeneity among studies was evaluated by the Chi-square-based Q test and I² test. Values of 25%, 50%, and 75% value for I² represented low, moderate, and high heterogeneity, respectively [36]. If there was no significant heterogeneity (P-value >0.05 and I²<50%), the fixed-effect model was chosen to estimate the summary HR and 95% CI. Otherwise, the random-effect [37] model was used. Finally, Begg’s funnel plot and Egger’s test [38,39] were used to assess potential publication bias with the METABIAS command [40] in STATA. A P-value >0.05 was considered insignificance. The meta-analysis was performed using Stata 12.0 software (Stata, College Station, TX, USA).

Results

Literature retrieval

The flow chart of enrolled studies for systematic review and meta-analysis is shown in Figure S1. A total of 4061 studies were retrieved from three databases (PubMed, Embase, and ISI) after the exclusion of 417 duplications. Among the 4061 studies, 4034 were removed by screening the titles and abstracts. The remaining 27 publications were independently screened through two authors (Zhengtao Liu and Shuping Que). Ten papers were finally included in the review (Cohen’s Kappa = 0.724). The process and reasons for exclusion are shown in Figure S1.

Characteristics of the included studies

Twelve prospective cohort studies, included in ten literatures involving 206,678 participants and 16,249 all-cause deaths in the follow-up duration, were enrolled in the systematic review and meta-analysis (Table 1). Among the twelve studies, three were performed in Asia, seven were performed in Europe, and three were performed in the USA. The mean age of participants ranged from 42 to 85 years and the durations of follow-up ranged from 2 to 14 years. Seven studies reported on the association between ALT level and specific mortality caused by CV, cancer, and liver disease [3,11,13,14]. CV disease-related mortality was the major cause of mortality, with 4517 deaths in the follow-up (accounting for 27.8% of the overall mortality), followed by mortality due to cancer (3767 deaths, 22.6% of the overall mortality), and deaths due to liver disease (558 deaths, 3.43% of the overall mortality).

Most studies enrolled both men and women, except for a German [8] and Scottish study (WOSCOPS) [13] that only focused on men. Seven of the twelve studies defined their normal range of ALT levels (from 19 to 55 U/l). The percentage of participants within a self-defined normal range of ALT values ranged from 85.6% to 96% in respective studies. One publication excluded those infected with the hepatitis B virus (HBV) or hepatitis C virus (HCV) infectors [11]. Another publication (including two data clusters) excluded the ALT outlier subjects (higher than three times the cut-off value) [13]. The majority of enrolled studies adopted the HR as an observational indicator, except for two studies that applied RR as an observational indicator [3,8]. All the studies evaluated HRs (or RRs) and 95% CIs of mortality between participants with higher and lower ALT activity after adjusting confounding covariates. HRs evaluated in specific subgroups, classified by age or genders, were also presented if provided in enrolled literatures (Table 1). One Japanese study [4] reported the HR in a population categorized by median BMI and the HR was reevaluated in the whole population (Table 1).

Quality assessment results

All of the prospective studies were of high quality (NOS score >6). The average NOS score of the studies overall was 7.58. The quality assessment scores by NOS are shown in Table S2.

Meta-analysis

According to age and gender, seventeen, eight, four and four data clusters were extracted to evaluate the pooled HRs of all-cause, CV disease-related, cancer-related, and liver disease-related mortality, compared between participants with higher and lower ALT levels respectively (in overall, younger, and older subgroups; Figure 1). With regard to the HRs compared between participants with higher and lower ALT levels, the heterogeneities of HRs decreased from all-cause to disease-specific mortality. In addition, the heterogeneities of HRs in the younger population were larger than the older population (Figure 1). When pooling the dose-response HRs of all-cause, CV disease-related, cancer-related, and liver disease-related mortality per 5 U/l of ALT increment (Figure 2), heterogeneity significantly decreased in the older subgroup. However, the heterogeneity was still significant in the younger population. In the older population, negative associations were observed between ALT increment and all-cause, CV disease-related, cancer-related mortality (HR: 0.91, 95% CI: 0.83–0.94, for all-cause mortality; HR: 0.91, 95% CI: 0.85–0.96, for CV disease-related mortality; HR: 0.92, 95% CI: 0.86–0.98, for cancer-related mortality). Pooled HRs in the older population...
**Table 1.** Characteristics of enrolled cohort prospective studies included in meta-analysis.

| First author and publication year | Country | Population characteristic | Definition of normal ALT level (U/L) | Enrolled subjects (M/F) | Age (range, mean ± SD, years) | Outcome (events number) gender/age (years) | Follow up (years) | Comparison (U/L) HR (95%CI)* | Adjusted covariates |
|----------------------------------|---------|---------------------------|--------------------------------------|-------------------------|--------------------------------|---------------------------------------------|------------------|-----------------------------|---------------------|
| Arndt et al [8] (1998) Germany   | Construction workers referred | Not (7858/0) | 42.8 | All-cause (163) | >22/≤22 | 1.3(0.9–1.9) | Age, nationality, occupational group, smoking status, BMI, alcohol consumption |
| Kim et al [3] (2004) Korea       | Insured workers in Korea Medical subjects | 35–40 (142055) | 44.8 ± 6.7 | All-cause(3392)M | M: ≥ 100/≤ 20 | 5.2(4.2–6.4) | Age, BMI, smoking status, alcohol consumption |
|                                     | Korea Medical Insurance within | 35–40 (47522) | 420 ± 6.0 | CV-disease(52)F | F: 30–39/≤ 20 | 1.3(0.4–4.1) | glucose, serum total |
|                                     | Corporation normal range | 40–69 (4524) | 54.3 ± 8.1 | All-cause (214) | 10 | Below median 8.11 | Age, sex, BMI, smoking habit, drinking habit, SBP, medication for, hypertension, serum, total cholesterol, population, history of diabetes, people with lower and higher BMI |
| Elinav et al [15] (2006) Israel | Community residents men, women, | < 40 for (245/210) | 70 | All-cause(1466) | > median 0.67 | Sex, physical activity, health perception, diabetes mellitus, IHD, malignancy, CRF, anemia, smoking |
| Nalamura et al [4] (2006) Japan  | Community residents referred | Not (1531/2593) | 54.3 ± 8.1 | All-cause (214) | 10 | Below median 8.11 | Age, sex, BMI, smoking habit, drinking habit, SBP, medication for, hypertension, serum, total cholesterol, population, history of diabetes, people with lower and higher BMI |
| Schindhelm et al [9] (2007) Nether- | Community residents referred | Not (788/651) | 60.9 ± 7.2 | All-cause (143) | T3/T1 1.10 | Age, sex, alcohol-intake, |
| First author and publication year | Country | Population characteristic | Definition of normal ALT level (U/L) | Enrolled subjects (M/F) | Age (range, mean ± SD, years) | Outcome (events number) | Follow up (years) | Comparison (U/L) HR (95% CI)* | Adjusted covariates |
|---------------------------------|---------|---------------------------|--------------------------------------|-------------------------|-----------------------------|------------------------|---------------------|-------------------------------|-------------------|
| Ruhl et al [11] (2009)          | USA     | Community residents with men, (6953/7997) exclusion of ≤ 19 for exclusion of HBV and HCV women, HCV infectors | ≤ 30 for 14950 Normal ALT ≤ 19 for group: CV-disease (379) M | 45.3 ± 0.50 CV-disease (286) F | 85.6% of elevated Cancer (291) M | All-cause (1205) M | 8.8 Elevated ALT | 1.1 (0.62–1.9) Age, sex, race-ethnicity, BMI, waist-to-hip ratio, HBV and HCV status, smoking, alcohol use, caffeine, physical activity, CRP, transferrin saturation, education | smoking, physical activity, waist, triglycerides, SBP, fasting glucose, HDL-C |
| Rovinen et al [17] (2010)       | Finland | Community residents referred | Not 397 M: 75–91 All-cause (127) M & F: 75–90 | (138/259) | 5.8 M: ≥ 21/≤ 21 & F: ≥ 19/≤ 19 | 0.45 | (0.24–0.86) M: BMI, Charlson comorbidity index, mini-mental state, examination, peak expiratory flow, smoking, alcohol use, hemoglobin, glucose | F: Charlson comorbidity index, statin use, diabetes mellitus, DBP, hemoglobin, LDL-C, HDL-C | |
| Ford et al- WOSCOPS (2011)      | Scotland | Participants in trial largely with exclusion of ALT outlier | ≤ 165 IU/L | 6595/0 45–64 All-cause (1293) 49 Q4/Q1 | 55.24–90 CV-disease (377) | 4.9 Q4/Q1 | (≥ 27/≤ 17) | 0.86 | Treatment allocation, age, history of angina, history of hypertension, smoking status, BMI | |

*HR denotes hazard ratio.
Table 1. Cont.

| First author and publication year | Country | Population characteristic | Enrolled subjects (M/F) | Age (range, mean ± SD, years) | Outcome (events number) | Follow up (years) | Comparison (U/L) HR (95%CI)* | Adjusted covariates |
|-----------------------------------|---------|---------------------------|-------------------------|-------------------------------|------------------------|-----------------|-------------------------------|-------------------|
| Ford et al- Scotland, 2011        | Cancer (532) | ≤55 largely 5804 | 70–82 | All-cause (604) | 3.2 | Q4/Q1 | 0.82 | SBP, DBP, HDL-C, LDL-C, log(triglycerides), glucose, nitrate use, socioeconomic deprivation, alcohol use |
| PROSPER [13], Ireland, clinical trial of pravastatin within (2803/3001) | Cancer (206) | 75.3 ± 3.3 | CV-disease (216) | 0.58 | Sex, BMI, DBP, HDL-C, LDL-C, log(triglycerides), glucose, alcohol consumption |
| Schooling et al, USA, residents referred (7888/8966) | Cancer (2199) | 49.8 ± 22.9 | T1: All-cause (1906) | F:T3/T1 | 0.89 (0.70–1.12) | Age, gender, race/ethnicity, education, smoking |
| [14], 2012 | Cancer (2729) | 46.9 ± 20.1 | T2: All-cause (266) | F:T3/T1 | 0.99 (0.85–1.14) | Status, alcohol use |
| | Cancer (1110) | 50–75 yr | T3: All-cause (1110) | F:T3/T1 | 0.96 (0.76–1.22) | Age, gender, race/ethnicity, education, smoking |
| | CV-disease (974) | 50–75 yr | T3: All-cause (974) | F:T3/T1 | 0.87 (0.75–1.01) | Status, alcohol use |
| | CV-disease (889) | 75–87 yr | T3: All-cause (889) | F:T3/T1 | 0.86 (0.66–1.11) | Age, gender, race/ethnicity, education, smoking |
### Table 1. Cont.

| First author and publication year | Country    | Population characteristic | Definition of normal ALT level (U/L) | Enrolled subjects (M/F) | Age (range, mean±SD, years) | Outcome (events number) gender/age (years) | Follow up (years) | Comparison (U/L)HR (95%CI) | Adjusted covariates |
|-----------------------------------|------------|-----------------------------|--------------------------------------|-------------------------|-----------------------------|---------------------------------------------|------------------|-----------------------------|---------------------|
| Koehler et al [18]                | Netherland | Community                   | CV-disease(58)<50 yr                 | 5186                    | 70.3±9.1                    | All-cause (2997) 14 P95/P25                | 0.92             | Age, sex, education, smoking status, alcohol intake, hypertension, diabetes mellitus, BMI, total |                     |
| (2013)                            | land       | residents                   | CV-disease (436) 50–75 yr            | 30 for                  |                             |                                             |                  |                             |                     |
|                                   |            |                             | CV-disease (1369)>75 yr              | 30 for                  |                             |                                             |                  |                             |                     |
|                                   |            |                             |                                                                                   | (3195/1991)             |                             |                                             |                  |                             |                     |
|                                   |            |                             |                                                                                   |                         |                             |                                             |                  |                             |                     |

Two studies [3,8] only provided RR as observational indicator. RR was treated as HR unless specific notification.

The median BMI in study was 22.7 kg/m².

T1 represented the subjects with lowest category of ALT value (<13 U/l for men and <9 U/l for women).

T2 represented the subjects with middle category of ALT value (13–21 U/l for men and 9–15 U/l for women).

T3 represented the subjects with highest category of ALT value (>21 U/l for men and >15 U/l for women).

Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; CI: confidence interval; CRF: chronic renal failure; CRP: C-reactive protein; CV: cardiovascular; DBP: diastolic blood pressure; F: female; HbA1c: glycated haemoglobin; HBV: hepatitis B virus; HCV: hepatitis C virus; HDL-C: high-density lipoprotein cholesterol; HR: hazard ratio; IHD: ischemic heart disease; LDL-C: low density lipoprotein cholesterol; M: male; P: percentile; Q: quartile; SBP: systolic blood pressure; SD: Standard deviation; T: tertile; U/l: units per liter; yr: year.

doi:10.1371/journal.pone.0091410.t001
were much lower than HRs in younger people (all heterogeneity between subgroups P<0.001, Figure 3). In younger adults, moderately elevated HRs of all-cause mortality (HR: 1.06, 95% CI: 1.06–1.07), CV-related mortality (HR: 1.03, 95% CI: 1.02–1.05), and cancer-related mortality (HR: 1.07, 95% CI: 1.06–1.08) per 5 U/l of ALT increment were observed with significant heterogeneity (Figure 2). Notably, high HRs of liver-disease related mortality per 5 U/l of ALT elevation were observed in every referred study (all in the younger population). An approximate increase of 24% in liver-disease related mortality with 5 U/l of ALT increment was observed (HR: 1.24, 95% CI: 1.23–1.25; Figure 2).

Furthermore, the quantitative impacts of age on the association between ALT variation and mortality (from all-cause, CV disease-related, and cancer-related) were evaluated by meta-regression analysis (Figure 3). Moderate but consistent inverse effects of age on HRs of all-cause, CV disease-related, and cancer-related mortality caused by ALT increment were observed. A decrease of approximately 4% on dose-response HRs of mortality related to all-cause (95% CI: 0.994–0.998), CV-disease (95% CI: 0.992–0.998), and cancer (95% CI: 0.994–0.998) followed with one year’s age increment were observed with significant trends (all P<0.05, Figure 3).

**Sensitivity and subgroup analyses**

Because high heterogeneity was present in the overall analysis, sensitivity analyses were conducted by stepwise omitting one study and re-evaluating the summary HRs of relative mortality on the residual studies to estimate the impact of a single study on combined results classified by age (Figure 4, Figure 5). In younger adults, the data clusters from Korean males [3] and the Scottish population with statin medication [13] were the outliers that caused the HRs of all-cause, CV disease-related, and cancer-related mortality deviated from the middle. Meanwhile, results reported in Korean males led to outlying liver-disease related mortality in the overall analysis (Figure 4). For older people, the
American and Dutch studies [14,18] also influenced the overall results; however, the impacts were lower than the outliers in younger adults (Figure 5). These outliers also contributed to the heterogeneity in subgroup analysis.

In the following sensitivity analysis, the pooled HRs were reevaluated after excluding the outliers by age (Table 2). The heterogeneity decreased to insignificance in most ALT-mortality associations, except for the ALT-CV-disease mortality in the younger population (Table 2). The pooled HRs decreased further after excluding the outliers, except for the pooled HR of liver-disease related mortality caused by ALT elevation in the younger subgroup (Table 2). ALT activity lost its significant association with CV disease-related mortality after excluding the outliers in the younger population (HR: 1.01, 95% CI: 0.95–1.07; Table 2).

In addition, we attempted to evaluate the potential source of heterogeneity by subgroup analyses classified by age (mean age, 70/70 years). Potential covariates that might contribute to heterogeneity were estimated in the association between ALT activity and all-cause/cause specific mortality in subgroup analysis (Table 3, Table 4). In the younger population, the pooled HR of all-cause, CV disease-related, and cancer-related mortality was unstable and inconsistent in subgroup analysis classified by ethnicity, sample size, and statin medication (Table 3). Notably, the HRs of all-cause, CV disease-related, and cancer-related mortality were much higher in Asians and populations without statin medication. The pooled RRs of all-cause, CV disease-related, and cancer-related mortality were much higher than the pooled HRs (all $P<0.001$, Table 3). In the older population, the pooled HRs were more stable than younger adults. A significant and negative association was still observed in separate subgroups, except in the subgroup with a smaller sample size ($<1000$), without adjusting for alcohol intake (on ALT-CV disease-related mortality association, Table 4). The significant heterogeneity on HRs of all-cause mortality between subgroups classified by potential confounders might originate from the outliers [14,18]. In addition, the inter-group heterogeneities decreased to insignifi-
Figure 3. Meta-regression analyses on ALT-mortality association by age. A represented the impact of age on ALT-all cause mortality association (coefficient: 0.996, 95%CI: 0.994–0.998); B represented the impact of age on ALT-CV related mortality association (coefficient: 0.996, 95%CI: 0.992–0.998); C represented the impact of age on ALT-cancer related mortality (coefficient: 0.996, 95%CI: 0.992–0.998).

doi:10.1371/journal.pone.0091410.g003
icance when the subgroup analysis was performed after excluding the outliers (all \(P>0.05\), data not shown).

**Assessment of publication bias**

To assess the publication bias, Begg’s funnel plot (Figure 6) and Egger’s test were used. No significant publication bias was observed (Egger’s \(P=0.936\); Figure 6).

**Discussion**

This is the first systematic review and meta-analysis to assess the complex association between ALT activities and ensuing all-cause/disease-specific (including CV disease, cancer, and liver-disease) mortality in prospective cohort studies. Twelve studies were examined and included a total of 206,678 participants and 16,249 deaths. In all the enrolled studies, age was an independent covariate influencing the dose-response association between ALT activity and all-cause, CV disease-related, and cancer-related mortality with a moderate but consistent impact in meta-regression analysis (Figure 3). An approximate decrease of 4% in dose-response HRs of mortality caused by ALT elevation was observed followed with one year’s increment (all \(P<0.05\)). Hence, the enrolled studies were divided into two subgroups by mean age (<70/\(\geq 70\) years). In the younger population, the HR of mortality from liver disease was 1.24 (95% CI: 1.23–1.25) with 5 U/l of ALT increment (Figure 2D). Conversely, an approximate decrease of 8–9% in all-cause, CV disease-related, and cancer-related mortality was observed, associated with a 5 U/l ALT elevation with low heterogeneity in older population (Figure 2). Overall, the heterogeneity of pooled HRs was more obvious in younger adults (Figure 1, Figure 2). Compared to the older population, significantly higher dose-response HRs for all-cause,

![Figure 4. Sensitivity analyses by stepwise omitting each study at a time in younger adults.](https://doi.org/10.1371/journal.pone.0091410.g004)
CV disease-related, and cancer-related mortality was observed in younger subgroups (all \( P < 0.01 \); Figure 2).

In younger adults, the ALT activity was weakly, unstably, and inconsistently associated with all-cause, CV disease-related, and cancer-related mortality, even after excluding the outliers. The inclusion of Korean male participants [3] significantly increased the pooled results, possibly because of the relatively higher occurrence of liver-disease related deaths, which might be linked to the high prevalence of HBV infection observed in that specific population [41]. Otherwise, the population using statin medication in the Scottish study [13] might also influence and cause a decrease in the pooled HRs. However, these impacts were limited and the pooled HRs were still low after excluding the outliers. In previous studies, ALT activity was considered useful in predicting the overall health and mortality risk [1,26]. Through meta-analysis on all relative studies, the associations between ALT activity and all-cause/disease-related (including CV-disease and cancer) mortality were inconsistent, susceptible to many covariates and weak in synthesizing the dose-response HRs from different studies. Accordingly, the results indicated that ALT was not an available predictor when using all-cause or non-hepatic death as the observational endpoints in epidemiological surveys of the younger population. However, further investigations are needed.

In contrast, the ALT activity was strongly linked to liver disease-related death, even after excluding the participants with viral hepatitis [11]. ALT activity is more hepatic-specific than other liver enzymes (e.g., aspartate aminotransferase [AST], gamma-glutamyltransferase [GGT]) and sensitive in predicting liver disease [2,42]. ALT elevation is indicative of apparent or latent liver disease (such as non-alcoholic fatty liver disease [NAFLD], alcoholic liver disease [ALD] and viral hepatitis infection [43–45]), which might cause more deaths in the general population. However, the significant risk of liver disease-related mortality caused by ALT elevation was reported to exhibit a huge discrimination due to distinctions in enrollment and comparison (Figure 1D). In this study, the ALT elevation was standardized and an approximate increase of 43% in liver-disease related mortality was observed to follow the same extent of ALT elevation (per 5 U/l) after excluding the outliers (results from the Korean male population [3] with a high prevalence of HBV infection [41]). This indicated that ALT elevation is closely associated with liver disease-related mortality.

**Table 2.** Sensitivity analysis on pooled HR of mortality after excluding the outliers classified by age.

| Group | Number of data clusters (n) | HR*(95%CI) | \( I^2 \) (%) | \( P \) |
|-------|-----------------------------|------------|---------------|-------|
| Younger subgroup (mean age < 70 years) | | | | |
| All-cause mortality | | | | |
| Studied with no exclusion | 7 | 1.06(1.06–1.07) | 94.7 | <0.001 |
| Studies except the Korean outlier [3] | 6 | 1.01(0.99–1.02) | 83.5 | <0.001 |
| Studies except the Korean and Scottish outliers [3,13] | 5 | 1.05(1.03–1.07) | 0 | 0.781 |
| CV mortality | | | | |
| Studies with no exclusion | 5 | 1.03(1.02–1.05) | 74.4 | 0.004 |
| Studies except the Korean outlier [3] | 4 | 0.99(0.95–1.02) | 52.0 | 0.100 |
| Studies except the Korean and Scottish outliers [3,13] | 3 | 1.01(0.95–1.07) | 59.9 | 0.085 |
| Cancer mortality | | | | |
| Studies with no exclusion | 5 | 1.07(1.06–1.08) | 90.9 | <0.001 |
| Studies except the Korean outlier [3] | 4 | 1.00(0.97–1.02) | 71.1 | 0.016 |
| Studies except the Korean and Scottish outliers [3,13] | 3 | 1.04(1.00–1.08) | 0 | 0.709 |
| Liver disease mortality | | | | |
| Studies with no exclusion | 3 | 1.24(1.23–1.25) | 83.7 | 0.002 |
| Studies except the Korean outlier [3] | 2 | 1.43(1.32–1.55) | 0 | 0.520 |
| Older subgroup (mean age ≥ 70 years) | | | | |
| All-cause mortality | | | | |
| Studied with no exclusion | 7 | 0.75(0.68–0.82) | 58.6 | 0.025 |
| Studies except the American and Dutch outliers [14,18] | 5 | 0.63(0.54–0.73) | 0 | 0.822 |
| CV mortality | | | | |
| Studies with no exclusion | 4 | 0.75(0.63–0.87) | 24.4 | 0.266 |
| Studies except the American and Dutch outliers [14,18] | 2 | 0.60(0.37–0.83) | 0 | 0.593 |

*HR calculated in younger subgroup was the dose-response evaluation assessed per 5 U/l of ALT increment; HR calculated in older subgroup was the evaluation compared between higher and lower ALT categories.

Abbreviations: CI: confidence interval; CV: cardiovascular; HR: hazard ratio.

doi:10.1371/journal.pone.0091410.t002
Table 3. Subgroup analysis on HRs of mortality in younger population (mean age < 70 years).

| Group                      | Number of data clusters (n) | HR (95%CI)       | $\tau^2$ (%) | P value for heterogeneity in subgroups | P value for heterogeneity between subgroups |
|----------------------------|-----------------------------|------------------|--------------|----------------------------------------|---------------------------------------------|
| **All-cause mortality**    |                             |                  |              |                                        |                                             |
| Gender                     |                             |                  |              |                                        |                                             |
| Male                       | 4                           | 1.07(1.06–1.07)  | 97.2         | <0.001                                 |                                             |
| Female                     | 2                           | 1.05(1.02–1.08)  | 0            | 0.836                                  | 0.290                                       |
| Race/ethnicity             |                             |                  |              |                                        |                                             |
| Asian                      | 3                           | 1.09(1.08–1.09)  | 69.7         | 0.037                                  |                                             |
| Non-Asian                  | 4                           | 0.98(0.96–1.00)  | 54.2         | 0.088                                  | <0.001                                      |
| Follow-up (mean year)      |                             |                  |              |                                        |                                             |
| <8                         | 4                           | 1.06(1.06–1.07)  | 97.3         | <0.001                                 |                                             |
| $\geq$8                    | 3                           | 1.05(1.02–1.09)  | 0            | 0.419                                  | 0.545                                       |
| Sample size (n)            |                             |                  |              |                                        |                                             |
| <10000                     | 5                           | 0.99(0.98–1.01)  | 79.8         | 0.001                                  |                                             |
| $\geq$10000                | 2                           | 1.09(1.08–1.10)  | 83.7         | 0.013                                  | <0.001                                      |
| Statin medication          |                             |                  |              |                                        |                                             |
| No                         | 6                           | 1.08(1.07–1.09)  | 57.1         | 0.040                                  |                                             |
| Yes                        | 1                           | 0.97(0.95–0.99)  | none         | none                                   | <0.001                                      |
| Adjustments of MetS components$^b$ |                   |                  |              |                                        |                                             |
| No                         | 2                           | 1.06(1.03–1.10)  | 0            | 0.654                                  |                                             |
| Yes                        | 5                           | 1.06(1.06–1.07)  | 96.5         | 0                                      | 0.966                                       |
| Observational indicator    |                             |                  |              |                                        |                                             |
| RR                         | 3                           | 1.09(1.08–1.09)  | 71.5         | 0.030                                  |                                             |
| HR                         | 4                           | 0.99(0.97–1.01)  | 82.8         | 0.001                                  | <0.001                                      |
| CV-mortality               |                             |                  |              |                                        |                                             |
| Gender                     |                             |                  |              |                                        |                                             |
| Male                       | 3                           | 1.03(1.02–1.05)  | 87.1         | <0.001                                 |                                             |
| Female                     | 2                           | 1.04(1.08–1.11)  | 0            | 0.881                                  | 0.757                                       |
| Race/ethnicity             |                             |                  |              |                                        |                                             |
| Asian                      | 2                           | 1.05(1.03–1.07)  | 0            | 1                                      |                                             |
| Non-Asian                  | 3                           | 0.98(0.94–1.01)  | 52.5         | 0.122                                  | 0.001                                       |
| Follow-up (mean year)      |                             |                  |              |                                        |                                             |
| <8                         | 3                           | 1.04(1.02–1.06)  | 80.4         | 0.006                                  |                                             |
| $\geq$8                    | 2                           | 0.99(0.91–1.07)  | 75.0         | 0.045                                  | 0.237                                       |
| Sample size (n)            |                             |                  |              |                                        |                                             |
| <10000                     | 3                           | 0.98(0.94–1.01)  | 52.5         | 0.122                                  |                                             |
| $\geq$10000                | 2                           | 1.05(1.03–1.07)  | 0            | 1                                      | 0.001                                       |
| Statin medication          |                             |                  |              |                                        |                                             |
| No                         | 4                           | 1.05(1.03–1.07)  | 52.0         | 0.100                                  |                                             |
| Yes                        | 1                           | 0.97(0.93–1.01)  | None         | None                                   | 0.002                                       |
| Observational indicator    |                             |                  |              |                                        |                                             |
| RR                         | 2                           | 1.05(1.03–1.07)  | 0            | 1                                      |                                             |
| HR                         | 3                           | 0.97(0.93–1.01)  | 52.5         | 0.122                                  | 0.001                                       |
| Cancer-mortality           |                             |                  |              |                                        |                                             |
| Gender                     |                             |                  |              |                                        |                                             |
| Male                       | 3                           | 1.07(1.06–1.08)  | 95.3         | 0                                      |                                             |
| Female                     | 2                           | 1.04(1.00–1.09)  | 0            | 0.409                                  | 0.255                                       |
| Race/ethnicity             |                             |                  |              |                                        |                                             |
| Asian                      | 2                           | 1.08(1.07–1.09)  | 38.5         | 0.202                                  |                                             |
| Non-Asian                  | 3                           | 0.97(0.94–1.00)  | 9.4          | 0.331                                  | <0.001                                      |
| Follow-up (mean year)      |                             |                  |              |                                        |                                             |
With regard to the older samples, significant negative associations were observed between ALT activity and all-cause/disease-specific (including CV disease, cancer) mortality after synthesizing the dose-response HRs (Figure 2). An approximate 9–9% decrease in all-cause, CV disease-related and cancer-related mortality followed with 5 U/l of ALT increment (mostly in the normal range) was observed after pooling the reported HRs. Furthermore, these inverse associations were still significant even after adjusting the MetS components (Table 4). This phenomenon was first observed by Elinav et al in 2006 [15] and confirmed by several research studies [13,14,18,19] thereafter. The mechanism responsible for the inverse association between ALT level and mortality remains uncertain. Recently, an ultra low ALT level was considered a biomarker of an exaggerated hepatic aging process [15,22], including a reduction in liver size, blood flow, regeneration, and alexipharmic functions in hepatic aspects [24,46]. It was also implied in frailty and poor nutritional conditions [19], which might induce more deaths. Elevated ALT level is strongly associated with the increasing prevalence of MetS, which is linked to higher mortality in older population [47,48]. Accordingly, elevated ALT activity is theoretically related to a higher mortality. However, the inverse association between ALT activity and mortality was still statistically significant after adjusting for the MetS covariates (Table 4), indicating that the ALT level might be more representative of aging and frailty in the older population.

Notably, two studies [14,19] significantly influenced the pooled results and introduced more heterogeneity in the older population. One HR was calculated between the subjects with upper tertile and the lower tertile of ALT category, and the extremely high ALT was not excluded [14]. Another mortality comparison was performed between the participants in the top 5% (>33 U/l) higher than the health range previously recommended before [49,50] and the bottom 5% category of ALT levels [18]. In general, the inclusion of participants with ALT outliers in these two studies might confound the pooled results. Otherwise, four studies [13,15,18,19] of older populations specifically defined the normal range of ALT value (Table 1). In addition, the decreased pooled HR and heterogeneity in subgroups with participants mainly in the self-defined normal range of ALT levels (Table 4) implied that lower ALT levels might be more associated with higher mortality in older populations when making comparisons based on a normal range based in the published literature. Recently, deep concerns have been raised on the association between extremely low ALT levels and higher mortality, especially in the older populations [25]. Similar to previous studies [13,15,17], results in this study confirmed the inverse association and quantitatively estimated the dose-response risk of all-cause mortality and disease-specific (CV disease and cancer) mortality in older adults (Figure 2). The upper limit of normal (ULN) values for ALT level has been defined in given population in prior population-based studies [49–52]. However, no study has focused on the lower limit of normal of ALT levels, and an appropriate age-specific lower limit for a normal ALT level is necessary to enhance the predictive value of ALT as a common biomarker used in the health care of older subjects. The inverse association between ALT level and mortality warrants further investigation.

Remarkably, age showed a crucial impact on the association between ALT level and the ensuing all-cause/disease-specific mortality (all P<0.05, Figure 3). The dose-response HRs of mortality caused by ALT elevation were quantitatively assessed, and a 4% decreases in these HRs were observed with moderate but consistent effects followed with one year’s age increment (Figure 3). The mechanisms on how age affects the ALT-mortality association are not fully understood. One possibility is that ALT activity is more liver-specific and that ALT elevation is more indicative of death from apparent or latent liver disease, rather than all-cause mortality in younger adults (Figure 2D). Another explanation is that, with increasing age, decreases in ALT levels might be more representative of aging and frailty in overall health (independent of its traditional role in screening for liver function) [20,21]. Similar to prior hypotheses [26], we speculate that the clinical significance of ALT activity is affected by age and that the meta-regression proved this impact (Figure 3).

Except for age, the inconsistence of covariates, including the characteristics of enrolled participants and the observational index, might also confound the ALT-mortality association and should be taken into consideration. ALT elevation is often associated with MetS, alcoholic intake, and medication.

**Table 3.** Cont.

| Group | Number of data clusters (n) | HR* (95%CI) | I² (%) | P value for heterogeneity in subgroups | P value for heterogeneity between subgroups |
|-------|---------------------------|-------------|--------|--------------------------------------|------------------------------------------|
| <8    | 3                         | 1.07(1.06–1.08) | 95.3   | <0.001                               |                                          |
| ≥8    | 2                         | 1.02(0.94–1.11) | 0      | 0.533                                | 0.281                                    |
| Sample size (n) |                     |                      |        |                                      |                                          |
| <10000| 3                         | 0.97 (0.94, 1.00)   | 9.4    | 0.331                                |                                          |
| ≥10000| 2                         | 1.08 (1.07, 1.09)   | 38.5   | 0.202                                | <0.001                                  |
| Statin medication |                     |                      |        |                                      |                                          |
| No    | 4                         | 1.08 (1.07, 1.09)   | 17.5   | 0.304                                |                                          |
| Yes   | 1                         | 0.96 (0.92, 1.00)   | None   | None                                 | <0.001                                  |
| Observational indicator |                   |                      |        |                                      |                                          |
| RR    | 2                         | 1.08 (1.07, 1.09)   | 38.5   | 0.202                                |                                          |
| HR    | 3                         | 0.97 (0.94, 1.00)   | 9.4    | 0.331                                | <0.001                                  |

*the HR of mortality was dose-respended per 5 U/l of ALT increment.

**Table 3.** Cont.

| Group | Number of data clusters (n) | HR* (95%CI) | I² (%) | P value for heterogeneity in subgroups | P value for heterogeneity between subgroups |
|-------|---------------------------|-------------|--------|--------------------------------------|------------------------------------------|
| <8    | 3                         | 1.07(1.06–1.08) | 95.3   | <0.001                               |                                          |
| ≥8    | 2                         | 1.02(0.94–1.11) | 0      | 0.533                                | 0.281                                    |
| Sample size (n) |                     |                      |        |                                      |                                          |
| <10000| 3                         | 0.97 (0.94, 1.00)   | 9.4    | 0.331                                |                                          |
| ≥10000| 2                         | 1.08 (1.07, 1.09)   | 38.5   | 0.202                                | <0.001                                  |
| Statin medication |                     |                      |        |                                      |                                          |
| No    | 4                         | 1.08 (1.07, 1.09)   | 17.5   | 0.304                                |                                          |
| Yes   | 1                         | 0.96 (0.92, 1.00)   | None   | None                                 | <0.001                                  |
| Observational indicator |                   |                      |        |                                      |                                          |
| RR    | 2                         | 1.08 (1.07, 1.09)   | 38.5   | 0.202                                |                                          |
| HR    | 3                         | 0.97 (0.94, 1.00)   | 9.4    | 0.331                                | <0.001                                  |

*the HR of mortality was dose-respended per 5 U/l of ALT increment.
### Table 4. Subgroup analysis on HRs of mortality in older population (mean age ≥ 70 years).

| Group                              | Number of data clusters(n) | HR (95%CI)      | I² (%) | P value for heterogeneity in subgroups | P value for heterogeneity between subgroups |
|------------------------------------|-----------------------------|-----------------|--------|----------------------------------------|---------------------------------------------|
| **All-cause mortality**            |                             |                 |        |                                        |                                             |
| Comparison                         |                             |                 |        |                                        |                                             |
| Up than median/below median ALT    | 3                           | 0.60(0.44–0.76) | 0      | 0.534                                  |                                             |
| Highest/lowest ALT                 | 4                           | 0.78(0.71–0.86) | 66.8   | 0.029                                  | 0.041                                       |
| **Follow-up (mean year)**          |                             |                 |        |                                        |                                             |
| <10                                | 4                           | 0.62(0.52–0.73) | 0      | 0.706                                  |                                             |
| ≥10                                | 3                           | 0.85(0.76–0.95) | 32.4   | 0.228                                  | 0.001                                       |
| **Sample size (n)**                |                             |                 |        |                                        |                                             |
| <1000                              | 4                           | 0.62(0.50–0.75) | 0      | 0.681                                  |                                             |
| ≥1000                              | 3                           | 0.81(0.72–0.90) | 71.3   | 0.031                                  | 0.014                                       |
| **Statin medication**              |                             |                 |        |                                        |                                             |
| No                                 | 6                           | 0.78(0.70–0.85) | 58.9   | 0.033                                  |                                             |
| Yes                                | 1                           | 0.64(0.48–0.80) | none   | none                                   | 0.127                                       |
| **Adjustments of MetS components c**|                             |                 |        |                                        |                                             |
| No                                 | 4                           | 0.76(0.66–0.86) | 62.3   | 0.047                                  |                                             |
| Yes                                | 3                           | 0.73(0.64–0.83) | 68.6   | 0.041                                  | 0.702                                       |
| **Adjustment of alcohol intake**   |                             |                 |        |                                        |                                             |
| No                                 | 3                           | 0.66(0.52–0.79) | 0      | 0.966                                  |                                             |
| Yes                                | 4                           | 0.78(0.70–0.87) | 74.5   | 0.008                                  | 0.105                                       |
| **Subjects mainly in normal range d**|                             |                 |        |                                        |                                             |
| No                                 | 4                           | 0.82(0.73–0.92) | 66.5   | 0.030                                  |                                             |
| Yes                                | 3                           | 0.65(0.55–0.76) | 0      | 0.974                                  | 0.019                                       |
| **CV-mortality**                   |                             |                 |        |                                        |                                             |
| Follow-up (mean year)              |                             |                 |        |                                        |                                             |
| <10                                | 2                           | 0.60(0.37–0.83) | 0      | 0.593                                  |                                             |
| ≥10                                | 2                           | 0.82(0.69–0.95) | 0      | 0.761                                  | 0.104                                       |
| **Sample size (n)**                |                             |                 |        |                                        |                                             |
| <1000                              | 1                           | 0.80(0.30–1.57) | none   | none                                   |                                             |
| ≥1000                              | 3                           | 0.76(0.65–0.88) | 33.5   | 0.223                                  | 0.927                                       |
| **Statin medication**              |                             |                 |        |                                        |                                             |
| No                                 | 3                           | 0.82(0.69–0.95) | 0      | 0.954                                  |                                             |
| Yes                                | 1                           | 0.58(0.34–0.82) | none   | none                                   | 0.088                                       |
| **Adjustments of MetS components c**|                             |                 |        |                                        |                                             |
| No                                 | 1                           | 0.81(0.67–0.95) | none   | none                                   |                                             |
| Yes                                | 3                           | 0.68(0.48–0.87) | 0      | 0.401                                  | 0.276                                       |
| **Adjustment of alcohol intake**   |                             |                 |        |                                        |                                             |
| No                                 | 1                           | 0.80(0.34–1.88) | none   | none                                   |                                             |
| Yes                                | 3                           | 0.76(0.65–0.88) | 33.5   | 0.223                                  | 0.927                                       |
| **Subjects mainly in normal range d**|                             |                 |        |                                        |                                             |
| No                                 | 2                           | 0.82(0.69–0.95) | 0      | 0.761                                  |                                             |
| Yes                                | 2                           | 0.60(0.37–0.83) | 0      | 0.593                                  | 0.104                                       |

*HR was evaluated between higher and lower ALT categories.

1) “Up than median/below median ALT” represented comparison between population with ALT value higher than median level and population with ALT value below the median level (ALT level was continuous); “Highest/lowest ALT” represented comparison between population with ALT value in the highest category and population with ALT value in the lowest category (ALT level was continuous).

2) The adjusted MetS components were defined by NCEP-ATP-III criteria [35]; “Yes” represented four or more MetS covariates adjusted; “No” represented less than four MetS covariates adjusted.

3) “No” represented the study not defined the “normal range” of ALT level or 95% of subjects were in the self-defined “normal range” of ALT level; “Yes” represented the study defined the “normal range” of ALT level and 95% (or large part) of subjects were in the self-defined “normal range” of ALT level.

4) Abbreviations: ALT: alanine aminotransferase; CI: confidence interval; CV: cardiovascular; HR: hazard ratio.

doi:10.1371/journal.pone.0091410.t004
Inconsistency in these variables during enrollment might interfere and introduce biases on the final results. MetS is a series of metabolic disorders, including obesity, dyslipidemia, hyperglycemia, and hypertension, commonly defined by the NCEP-ATP-III criteria [35]. The ALT-mortality association might be influenced by these metabolic disorders in the MetS patients [56]. However, the trend did not reverse when subgroup analysis was conducted adjusting four or more MetS components as covariates in the younger and older population, indicating a limited impact of MetS status on the ALT-mortality association. In regard to alcohol intake, all the studies in the younger population adjusted for this variable. In studies with older participants, no significant differences were observed between studies with or without adjustments for alcohol intake (Table 4). The limited impacts of alcohol intake on the ALT-mortality association might be due to the lower alcohol intake amount and fewer heavy drinkers in the older population [57,58].

Two studies reported the ALT-mortality association in participants with moderate statin medication [13], which might cause slight liver toxicity manifested through a minor ALT elevation [59]. The influence of statin use on the ALT-mortality association is not fully clear. In this study, the effects of statin medication on the ALT-mortality association were inconsistent in different age groups. In younger adults, the statin medication might be a protective co-factor that decreased the risk of mortality (Table 3). Therefore, the pooled HRs of all-cause/disease-specific mortality were re-evaluated after excluding the outlier study [13]. These effects were attenuated in the older population and the heterogeneities of pooled HRs were no longer influenced by the study that enrolled participants taking statin medication (Table 4). With respect to observational indices, two studies [3,8] (both examining younger populations) adopted the RR instead of HR to evaluate the ALT-mortality association. Inferior to HR, the RR did not consider the “time to an event”, censored data, and may have caused a bias when pooled with HR [60]. Accordingly, a decreased heterogeneity of pooled HRs was observed in subgroup analysis divided by observational indicators (Table 3). However, the refined pooled HRs still implied the weak and unstable association between ALT level and all-cause/disease-specific mortality in younger population (Table 3).

GGT activity is another common liver enzyme activity also considered closely associated with all-cause and CV disease-related mortality in prior meta-analysis [61]. ALT activity is obviously inferior to GGT activity in predicting the mortality, especially in younger adults. However, the predictive value of GGT on CV-related mortality decreased and even lost significance in the older populations [62–64]. As a supplement, the predictive value of ALT activity in screening for long-term survival might remedy the deficiencies of GGT on risk assessment in older populations.

Our findings have strengths and applications for clinical practice. A qualified librarian helped with designing an extensive search strategy to decrease the omission of relevant references. In addition, the extremely low ALT activity within a normal range is also clinically relevant to all-cause and disease-related mortality in older people. This phenomenon indicates that not all patients with ALT measured within a normal range are safe and will alert clinicians to consider extremely low ALT value within a normal range more cautiously. The older population is a fast growing segment that consumes majority of health care resources [65]. The ALT measurement can aid in the prediction of long-term survival and aid clinicians in making full use of medical resources for cost effectiveness.

Besides the previous deficiencies mentioned, several limitations in this meta-analysis should be addressed. First, the HRs of ALT-related mortality in the older population were mainly obtained from the European populations [13,17]. For this reason, our results may not generalize well across other populations, such as the East Asians with a higher burden of HBV infection [66]. More studies in non-European older populations are thus required to confirm the association. Second, in addition to the intrinsic difference between ALT measurement assays performed at different institutes, heterogeneity observed in this study may be due to many factors, including differences in participant enrollment, sample size, statin medication use, follow-up lengths, and statistics used for comparisons. The subgroup analysis could not explain all the sources of heterogeneity, even when outlier studies were excluded. Third, the normal range of ALT levels were self-defined and distinguished. The negative ALT-mortality association was primarily obvious in older populations mainly within a self-defined normal range of ALT levels in subgroup analysis (Table 4). However, we could not evaluate the exact normal ALT range where the negative ALT-mortality association was established. Fourth, the prevalence of death from liver-disease is extremely low (558 deaths, accounting for 3.43% of the overall occurrence) and the previous statistical data was mainly collected in younger adults. The close ALT-liver disease mortality association might have less clinical and epidemiological implications in the whole population, and the impact of age on the association between ALT level and liver disease-related mortality was difficult to evaluate. However, it provided a clue that an ALT assay might be sensitive and valuable in mortality prediction, especially in younger patients with liver disease. Fifth, mortality, not disease incidence was used as measured outcome. Mortality is not a direct presentation of the natural history of certain diseases and interfered by the socioeconomic, rural-urban, and health behavior disparities between different districts [67–69]. Clinicians should consider these covariates and draw discreet conclusions when faced with a given population. Notably, pooled HRs could not be evaluated by individual participant data, which is more reliable, with potential advantages [70–72]. Information (e.g., age, gender, follow-up duration, and HR) was extracted as aggregate data rather than individual participant data in respective studies, which might cause larger heterogeneity and inconsistent analyses across studies [73]. Further meta-analysis using individual participant data is therefore needed.
In conclusion, this systematic review and meta-analysis on prospective cohort studies provides evidence that ALT activity is strongly associated with liver disease-related mortality independent of viral infection in younger populations. Unlike the inconsistency of the ALT-mortality association in the younger subgroup, extremely low ALT levels indicated a high all-cause/disease-specific (including CV disease and cancer) mortality, especially within the normal ALT range in the older population. The ALT-mortality associations are influenced by age and the HRs of all-cause/disease-specific (CV disease and cancer) mortality caused by ALT elevation decreased by age. More well-designed studies with strict enrollment are needed to further confirm our findings.

Supporting Information

Figure S1 Flow chart of selected studies for meta-analysis. Abbreviations: ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CVD: cardiovascular disease; DM: diabetes mellitus; GGT: gamma-glutamyl transpeptidase; JSE: Institute for Scientific Information; RR: relative risk.

Table S1 Search strategy for systematic review and meta-analysis of published literature on the association between alanine aminotransferase and all-cause/disease-specific mortality in general population.

References

1. Kim W, Flamm SL, Di Bisceglie AM, Bodenheimer HC (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47: 1363–1370.
2. Pratt DS, Kaplan MM (2000) Evaluation of abnormal liver-enzyme results in asymptomatic patients. New England Journal of Medicine 342: 1266–1271.
3. Hyson CK, Chung MN, Sun HJ, Kwang HH, Kyo Oh D, et al. (2004) Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328: 983.
4. Nakamura K, Okamura T, Kanda H, Hayakawa T, Okajama A, et al. (2006) Time course of changes in serum alanine aminotransferase levels and body mass index to predict mortality and medical costs: a 10-year follow-up study of National Health Insurance in Shiga, Japan. Journal of epidemiology 16: 15–20.
5. Lee TH, Kim W, Benson JT, Therneau TM, Melton LJ III (2008) Serum aminotransferase activity and mortality risk in a United States community. Hepatology 47: 380–387.
6. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP (2006) Elevated alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43: 1145–1151.
7. Olynyk JK, Kuinman MJ, Divittoli ML, Davis TM, Belily J, et al. (2009) Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. The American journal of gastroenterology 104: 1715–1722.
8. Arndt V, Brenner H, Rothenbacher D, Zechenderlin B, Fraiese E, et al. (1998) Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. International archives of occupational and environmental health 71: 405–412.
9. Schindhelm RK, Dekker JM, Nigels G, Boutier LM, Stenhoffen CD, et al. (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191: 391–396.
10. Goosling W, Masare JM, Vasan RS, D’Agostino Sr RB, Ellison RC, et al. (2008) Aminotransferase levels and 20-year risk of cardiovascular disease in an elderly population. PLoS ONE 3: e14254.
11. Ruhl CE, Everhart JE (2009) Elevated serum alanine aminotransferase and γ-glutamyltransferase and mortality in the United States population. Gastroenterology-Oortho 136: 477.
12. Yun KE, Shin CY, Yoon YS, Park HS (2009) Elevated serum alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 205: 533.
13. Ford I, Mozuaart SP, Lloyd S, Murray HM, Westendorp RG, et al. (2011) The association between alanine transaminase in the norm range and adverse cardiovascular and non-cardiovascular outcomes. International journal of epidemiology 40: 1530–1538.
14. Schooling CM, Kelvin EA, Jones HE (2012) Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Annals of Epidemiology.
15. Eslami E, Ackerman Z, Maasrai Y, Ben-Dov IZ, Ein-Mor E, et al. (2006) Low Alanine Aminotransferase Activity in Older People Is Associated with Greater Long-Term Mortality. Journal of the American Geriatrics Society 54: 1719–1724.
16. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, et al. (2009) Alanine aminotransferase, γ-glutamyltransferase, and incident diabetes: The British Women’s Heart and Health Study and meta-analysis. Diabetes Care 32: 741–750.
17. Hovinen SM, Pitkala KH, Tiilsis RS, Strandberg TE (2010) Alanine aminotransferase activity and mortality in older people. Journal of the American Geriatrics Society 58: 1399–1401.
18. Kochler EM, Sanna D, Hansen BE, Roos EF, Herrenga J, et al. (2013) Serum Liver Enzymes Are Associated With All-Cause Mortality In An Elderly Population, Liver International.
19. Le Couteur DG, Blyth FM, Creahey HM, Handelman DJ, Naganathan V, et al. (2010) The association of alanine transaminase with aging, frailty, and mortality. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 65: 712–717.
20. Dong MH, Bettencourt R, Barrett-Connor E, Loomba R (2012) Alanine aminotransferase decreases with age: the Rancho Bernardo Study. PLoS ONE 5: e14254.
21. Elinao F, Ben-Dov IZ, Ackerman E, Kielerman A, Glikerberg F, et al. (2005) Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. The American journal of gastroenterology 100: 2201–2204.
22. Yang MC, McLean AJ, Le Couteur DG (2002) Age-Related Alteration in Hepatic Disposition of the Neurotoxin 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydro-pyrididine and Pesticides. Pharmacology & toxicology 90: 203–207.
23. Schmucker DL (2005) Age-related changes in liver structure and function: implications for disease? Experimental gerontology 40: 650–659.
24. Marchosini G, Taegher G (2011) Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes—the lower, the better? International journal of epidemiology 40: 1539–1541.
25. Vento S, Nohel V (2008) Aminotransferases as predictors of mortality. The Lancet 371: 1022–1023.
26. Mohor D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 151: 264–269.
27. Stropshoff DF, Berlin JA, Morton SC, Ollin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology. JAMA: the journal of the American Medical Association 283: 2008–2012.
28. Wells G, Shea B, O’Connell D, Peterson P, Welch V, et al. (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute.
29. Sloe VN (1978) The International classification of diseases: ninth revision (ICD-9). Annals of internal medicine 88: 424–426.
30. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, et al. (2008) Meta-analysis: fixed-and random-effects meta-analysis. Stata Journal 8: 3.
31. Berlin JA, Longnecker MP, Greenland S (1995) Meta-analysis of epidemiologic dose-response data. Epidemiology 4: 218–226.
33. Oruini N, Bellocchio R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose–response data. Stata Journal 6: 40–57.
34. Sharp S (2012) Meta-analysis regression. Stata Technical Bulletin 7.
35. Program EsoTReNCE (2011) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285.
36. Hui WS, Liu Z, Ho SC (2010) Metabolic syndrome and all-cause mortality: a meta-analysis of clinical trials. Controlled clinical trials 7: 177–180.
37. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, et al. (2010) Estimation of the metabolic syndrome, the metabolic syndrome, and the risk of type 2 diabetes in older men. The American journal of human genetics 98: 960–967.
38. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics: 1088–1101.
39. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315: 629–634.
40. Steichen TJ (1986) Tests for publication bias in meta-analysis. Stata Technical Bulletin 7.
41. Lee BS, Cho YK, Jeong SH, Lee JH, Lee D, et al. (2013) Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. Journal of medical virology. 85: 741–747.
42. Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. Canadian medical association journal 172: 367–379.
43. Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. The American journal of gastroenterology 98: 969–976.
44. Perdino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, et al. (2005) Prevalence and etiology of altered liver tests: A population-based survey in a Mediterranean town. Hepatology 41: 1151–1159.
45. Cheu CH, Huang MH, Yang JC, Nien CK, Yang CC, et al. (2007) Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. Journal of gastroenterology and hepatology 22: 1482–1489.
46. Woodhouse K, Wynne H (1988) Age-related changes in liver size and hepatic blood flow. Clinical pharmacokinetics 15: 287–294.
47. Hui WS, Liu Z, Ho SC (2010) Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. European journal of epidemiology 25: 375–394.
48. Wannamethee SG, Shaper AG, Lennon I, Whincup PH (2005) Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28: 2913–2918.
49. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, et al. (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of internal medicine 137: 1–10.
50. Al-hamoudi W, Ali S, Hegab B, Elhiey H, Hashim A, et al. (2013) Revising the Upper Limit of Normal for Levels of Serum Alanine Aminotransferase in a Middle Eastern Population with Normal Liver Histology. Digestive diseases and sciences: 1–7.
51. Ruhl CE, Everhart JE (2012) Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 55: 447–454.
52. Limdil J, Hyde G (2003) Evaluation of abnormal liver function tests. Postgraduate medical journal 79: 307–312.
53. Liu Z, Que S, Ning H, Wang L, Peng T (2013) Elevated Alanine Aminotransferase Is Strongly Associated with Incident Metabolic Syndrome: A Meta-Analysis of Prospective Studies. PloS one 8.
54. Adams WL, Garry PJ, Rhyne R, Hunt WC (1990) Alcohol intake in the healthy elderly: Changes with age in a cross-sectional and longitudinal study. Journal of the American Geriatrics Society.
55. Molander RC, Yonker JA, Krailo DD (2010) Age-Related Changes in Drinking Patterns From Mid-to Older Age: Results From the Wisconsin Longitudinal Study. Alcoholism: Clinical and Experimental Research 34: 1182–1192.
56. Turrell G, Mathers C (2001) Socioeconomic inequalities in all-cause and specific-cause mortality among US youth: socioeconomic and rural–urban disparities and international patterns. Journal of Urban Health: 1–18.
57. Adams WL, Garry PJ, Rhyne R, Hunt WC (1990) Alcohol intake in the healthy elderly: Changes with age in a cross-sectional and longitudinal study. Journal of the American Geriatrics Society.
58. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, et al. (2005) Gamma-glutamyltransferase as a Risk Factor for Cardiovascular Disease Mortality An Epidemiological Investigation in a Cohort of 163 944 Austrian Adults. Circulation 112: 2130–2137.
59. Pappas G, Queen S, Hadden W, Fisher G (1993) The increasing disparity in mortality between serum gamma-glutamyltransferase and cardiovascular mortality varies by age: the Minnesota Heart Survey. European Journal of Cardiovascular Prevention & Rehabilitation 16: 16–20.
60. Khaw K-T, Wareham N, O’Connor P, D’Elia L, Khaw K, et al. (2008) Elevated gamma-glutamyltransferase and long-term survival: is it just the liver? Clinical chemistry 53: 940–946.
61. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, et al. (2004) Global epidemiology of hepatitis B virus. Journal of clinical gastroenterology 38: S136–S148.
62. Turrell G, Mathers C (2001) Socioeconomic inequalities in all-cause and specific-cause mortality in Australia: 1983–1987 and 1995–1997. International journal of epidemiology 30: 231–239.
63. Stewart LA (1995) Practical methodology of meta-analyses (overviews) using updated individual patient data. Statistics in medicine 14: 2057–2079.
64. Turrell G, Mathers C (2001) Socioeconomic inequalities in all-cause and specific-cause mortality in Australia: 1983–1987 and 1995–1997. International journal of epidemiology 30: 231–239.
65. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ British medical journal 340: 521–525.
66. Adams WL, Garry PJ, Rhyne R, Hunt WC (1990) Alcohol intake in the healthy elderly: Changes with age in a cross-sectional and longitudinal study. Journal of the American Geriatrics Society.
67. Turrell G, Mathers C (2001) Socioeconomic inequalities in all-cause and specific-cause mortality in Australia: 1983–1987 and 1995–1997. International journal of epidemiology 30: 231–239.
68. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ British medical journal 340: 521–525.